A pilot investigation on inflammatory markers and theta burst stimulation protocol interaction along a three-month recovery course following an isolated upper limb fracture
Cytokine, 2025
Robitaille B., Herrero Babiloni A., Jodoin M., Briand M., Rouleau D., De Beaumont L.
Disease area | Application area | Sample type | Products |
---|---|---|---|
Other Diseases & Syndromes | Pathophysiology | Serum | O Olink Explore 3072/384 |
Abstract
This study investigates the effects of theta burst stimulation (TBS) on inflammatory markers in patients with isolated upper limb fractures (IULF). Participants underwent a 10-day TBS intervention following a randomized matched pair design. Blood samples collected at three time points were analyzed for inflammatory biomarkers, mainly including interleukin-1 receptor antagonist (IL-1Ra), IL-1β, and IL-6. Results revealed a significant interaction between TBS and time for IL-1Ra, indicating a more pronounced decrease in IL-1Ra expression over time in the active TBS group. However, IL-6 levels decreased over time regardless of TBS intervention, suggesting a natural decline in response to injury. No significant interaction was found for IL-1β. While IL-1Ra levels were associated with higher functional disability prior to treatment initiation, active TBS intervention led to a decrease of IL-1Ra levels at both follow-up time points. These changes were not associated with alterations in pain or disability, suggesting that TBS may primarily influence recovery processes independent of pain modulation. Notably, IL-1β levels were negatively correlated with disability in the active TBS group at the 3-month follow-up. This study sheds light on the potential of TBS to modulate inflammatory responses in orthopedic trauma, emphasizing the need for further research to elucidate its therapeutic implications. Clinical Significance: TBS may offer a promising adjunctive therapy for promoting functional recovery in patients with upper limb fractures.